Clinical Trial Update: Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating denosumab in combination with a PD-1 inhibitor in stage III/IV melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• Denosumab (denosumab)
• PD-1 inhibitor

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Melanoma Stage Iii, Melanoma Stage Iv | Phase 2 | Status: COMPLETED | Results posted: 2024-08-12